1. Home
  2. CTNM vs UMAC Comparison

CTNM vs UMAC Comparison

Compare CTNM & UMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • UMAC
  • Stock Information
  • Founded
  • CTNM 2009
  • UMAC 2019
  • Country
  • CTNM United States
  • UMAC United States
  • Employees
  • CTNM N/A
  • UMAC N/A
  • Industry
  • CTNM
  • UMAC
  • Sector
  • CTNM
  • UMAC
  • Exchange
  • CTNM Nasdaq
  • UMAC Nasdaq
  • Market Cap
  • CTNM 328.1M
  • UMAC 267.7M
  • IPO Year
  • CTNM 2024
  • UMAC 2024
  • Fundamental
  • Price
  • CTNM $10.90
  • UMAC $15.32
  • Analyst Decision
  • CTNM Strong Buy
  • UMAC Strong Buy
  • Analyst Count
  • CTNM 5
  • UMAC 3
  • Target Price
  • CTNM $22.20
  • UMAC $19.33
  • AVG Volume (30 Days)
  • CTNM 93.7K
  • UMAC 5.2M
  • Earning Date
  • CTNM 11-06-2025
  • UMAC 11-14-2025
  • Dividend Yield
  • CTNM N/A
  • UMAC N/A
  • EPS Growth
  • CTNM N/A
  • UMAC N/A
  • EPS
  • CTNM N/A
  • UMAC N/A
  • Revenue
  • CTNM N/A
  • UMAC $7,701,550.00
  • Revenue This Year
  • CTNM N/A
  • UMAC $86.94
  • Revenue Next Year
  • CTNM N/A
  • UMAC $118.95
  • P/E Ratio
  • CTNM N/A
  • UMAC N/A
  • Revenue Growth
  • CTNM N/A
  • UMAC 279.38
  • 52 Week Low
  • CTNM $3.35
  • UMAC $1.45
  • 52 Week High
  • CTNM $20.24
  • UMAC $23.62
  • Technical
  • Relative Strength Index (RSI)
  • CTNM 46.91
  • UMAC 57.64
  • Support Level
  • CTNM $10.77
  • UMAC $13.45
  • Resistance Level
  • CTNM $11.34
  • UMAC $16.38
  • Average True Range (ATR)
  • CTNM 0.66
  • UMAC 1.60
  • MACD
  • CTNM -0.17
  • UMAC 0.12
  • Stochastic Oscillator
  • CTNM 27.31
  • UMAC 71.84

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About UMAC Unusual Machines Inc. Common Stock

Unusual Machines Inc is engaged in serving the American drone industry by building and selling drone components.

Share on Social Networks: